US FDA consults on selective collection of safety data in drug trials
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is seeking stakeholder feedback on a draft guideline that aims to help manufactures of drugs and biololgics determine the amount and types of safety data they should collect during late-stage pre-market and post-market trials1,2.